An analytical chemist by training, I started my career in the pharmaceutical industry. My responsibility: speed up medicinal chemists and their efforts in fast synthesis of new leads. Even back then, throughput and automation of structure identification have been critical issues à introduced overnight services and walk-up / OpenAccess offerings for LC-MS analysis

Later, changed sites and joined the Agilent Product Management: not buying and using analytical instrumentation, but developing new products and solutions. Since then, filled different roles. For the last 4 years, my focus as Marketing Director has been on topics around digital transformation and intelligent automation of E2E lab workflows.

CEO of PulpFixin.

I have dedicated my life to provide innovative tools, solutions and services to those who dedicate Their lives to the advancement of health, knowledge and the happiness of the human experience.
Currently I am focused on bringing sustainability to the scientific community by providing alternatives to traditional single use plastics. The goal is to replace fossil fuel based plastics with biodegradable if not compostable materials with an emphasis on paper due to the well established recycling infrastructure around the world.  If you can't recycle it, compost it!
As a lifetime consultant for streamlining & automating scientific workflows, I continue to help companies operate at the utmost efficiency while also helping to improve supply chains, reduce cost and meet sustainability goals.

Lorna Ewart, PhD is Chief Scientific Officer at Emulate. With more than two decades of experience in pharmaceutical R&D, Dr. Ewart has been a driving force in advancing bioscience and drug safety innovation. At Emulate, she leads the biological sciences division and plays a pivotal role in shaping the company’s scientific vision—guiding its collaborations across academia, industry, and regulatory agencies. Dr. Ewart’s deep expertise and leadership continue to push the boundaries of what’s possible in human-relevant models for drug development and translational research.

Steve Finkbeiner, MD, PhD, is director of the Center for Systems and Therapeutics and a senior investigator at Gladstone Institutes. In 2009, with support from Bay Area philanthropists, he established the Taube/Koret Center for Neurodegenerative Disease Research at Gladstone to accelerate the development of drug therapies for patients suffering from conditions such as Huntington’s disease. Finkbeiner is also director of the Hellman Family Foundation Alzheimer’s Disease Research Program and an investigator in the Roddenberry Stem Cell Center at Gladstone. In addition, he is a professor of neurology and physiology at UC San Francisco (UCSF).